ArticleJournal of gastrointestinal oncology2025
ZNF529 up-regulation speeds up progression and induces tyrosine kinase inhibitor resistance in hepatocellular carcinoma.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains a significant global health concern. Zinc finger protein 529 (ZNF529) may be associated with resistance to tyrosine kinase inhibitors (TKIs) in HCC. This study explored the expression of ZNF529 in HCC, its prognostic significance and its potential as a therapeutic target. We aimed to evaluate how the up-regulation of ZNF529 correlates with disease prognosis and drug resistance in HCC. Methods: We analysed 4,556 HCC and 3,304 non-cancerous liver samples using publicly available RNA sequencing and tissue microarray data. The messenger RNA (mRNA) expression of ZNF529 was quantified, and a summary receiver operating characteristic (sROC) curve was used to assess its discriminatory ability. Immunohistochemistry was applied to confirm the protein expression levels. In addition, a single-cell analysis and survival analysis were performed to further evaluate the clinical relevance of ZNF529 expression in HCC. Results: ZNF529 mRNA levels were significantly higher in HCC samples compared to non-cancerous liver tissue [standardized mean difference (SMD) =0.26, 95% confidence interval (CI): 0.14-0.38]. Immunohistochemistry results corroborated these findings with elevated protein levels, particularly in correlation with alpha-fetoprotein (AFP) expression. High expression of ZNF529 was associated with a significantly increased risk of poor prognosis in HCC [hazard ratio (HR) =1.94, 95% CI: 1.38-2.73]. ZNF529 was also up-regulated in TKI-resistant samples (SMD =0.63, 95% CI: 0.07-1.19). Functional enrichment analysis identified its involvement in RNA metabolism and cellular transport. Conclusions: Our findings suggest that ZNF529 is a promising prognostic biomarker for HCC. Its up-regulation correlates with poor prognosis, increased risk and resistance to TKI therapies. ZNF529 could serve as a potential therapeutic target, highlighting the need for further investigation into ZNF529-targeted therapies in HCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.